



Microparticle-Based Vaccines

Guest Editor:

Dr. Alejandro Marin-Lopez

Department of Internal Medicine,
Section of Infectious Diseases,
School of Medicine, Yale
University, New Haven, CT, USA

Deadline for manuscript
submissions:

closed (15 August 2022)

Message from the Guest Editor

Dear Colleagues,

This special issue will highlight and bring out the state of the art in the development of microparticle-based vaccines, a transcendent approach for vaccine design not only against infectious diseases, but also for stimulating immune responses against cancer.

Particulate carriers offer several attributes for use as vaccine delivery systems. First, microparticles can mimic the size of the pathogens that the immune system has evolved to combat and, consequently, they are efficiently better recognized and internalized by antigen presenting cells, facilitating the uptake of the antigens (or genetic material) carried. In addition, these particulate systems can present multiple copies of the antigens, not only on their surface but also forming part of the internal particle structure, protecting the antigens from degradation and increasing the antigen persistence.

As a guest editor of this Special Issue, I invite you to submit research and review articles related to this special edition, which will help researchers in the vaccinology field to develop and improve new vaccine strategies based in these particulate platforms.

Dr. Alejandro Marin-Lopez
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)